---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342388"
form_type: "8-K"
ticker: "MGX"
cik: "0001785279"
company_name: "Metagenomi Therapeutics, Inc."
filed_at: "2026-08-10T20:10:39+00:00"
generated_at: "2026-08-10T20:12:28.869052+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Metagenomi Q2 2026: $120.7M cash, IND for MGX-001 hemophilia A on track for 4Q 2026

## Summary
- Cash, equivalents, and marketable securities $120.7M as of June 30, 2026; runway through 4Q 2027.
- IND application for MGX-001 (hemophilia A) on track for 4Q 2026; IND-enabling studies expected complete by end of Q3 2026.
- R&D expenses flat at $22.5M YoY; G&A down to $6.0M from $7.0M in Q2 2025.
- Two scientific posters won Top Poster Awards at 2026 ISTH Congress in Paris.
- Plans to initiate clinical trials in 2027 subject to regulatory clearance.

## SEC filing metadata
- accession: 0001193125-26-342388
- form_type: 8-K
- ticker: MGX
- cik: 0001785279
- company_name: Metagenomi Therapeutics, Inc.
- filed_at: 2026-08-10T20:10:39+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785279/000119312526342388/0001193125-26-342388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785279/000119312526342388/mgx-20260810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342388
- JSON: https://secwatch.observer/filing/0001193125-26-342388.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342388.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.